Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

Overview of attention for article published in BMC Health Services Research, January 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 33 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 30 Jul 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 12 Jun 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.